This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dateki, S. Articles by Ogata, T. Search for Related Content PubMed PubMed Citation Articles by Dateki, S. Articles by Ogata, T. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology

OTX2 Mutation in a Patient with Anophthalmia, Short Stature, and Partial Growth Hormone Deficiency: Functional Studies Using the IRBP, HESX1, and POU1F1 Promoters

Department of Endocrinology and Metabolism (S.D., M.F., N.S., T.O.), National Research Institute for Child Health and Development, Tokyo 157-8535, Japan; Department of Pediatrics (S.D.), Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501; and Division of Endocrinology and Metabolism (K.M., M.A.), Kanagawa Children’s Medical Center, Yokohama 232-8555, Japan

Address all correspondence and requests for reprints to: Dr. T. Ogata, Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, 2-10-1 Ohkura, Setagaya, Tokyo 157-8535, Japan. E-mail: tomogata{at}nch.go.jp.

Context: OTX2 is a transcription factor gene essential for eye development. Although recent studies suggest the involvement of OTX2 in pituitary function, there is no report demonstrating a positive role of OTX2 in the pituitary function.

Objective: The objective of the study was to report the results of functional studies indicating the relevance of OTX2 to pituitary function.

Patient: A Japanese female patient with bilateral anophthalmia was found to have short stature (height, –3.3 SD) and isolated partial GH deficiency (peak serum GH 3.1 and 9.7 µg/liter after insulin and arginine stimulations, respectively; serum IGF-I 37 ng/ml) at 3 yr 9 months of age. Magnetic resonance imaging delineated apparently normal pituitary gland.

Results: Mutation analysis showed a de novo heterozygous frameshift mutation (c.402insC) that is predicted to retain the homeodomain but lose the transactivation domain. Functional studies revealed that the wild-type and mutant OTX2 proteins localized to the nucleus and bound to the target sequences within the IRBP (interstitial retinoid-binding protein), HESX1 (HESX homeobox 1), and POU1F1 promoters. Furthermore, the wild-type OTX2 protein markedly transactivated the promoters of IRBP (27-fold), HESX1 (4.5-fold), and POU1F1 (19-fold), whereas the mutant OTX2 protein barely retained the transactivation activities and had no dominant-negative effects.

Conclusions: The results provide direct evidence for OTX2 being involved in the pituitary function. It is likely that the heterozygous severe OTX2 loss-of-function mutation caused GH deficiency and short stature, primarily because of decreased transactivation function for HESX1 and POU1F1.